Merkel cell carcinoma (MCC) is a rare, clinically aggressive cutaneous neuroendocrine neoplasm with a high mortality rate. Though the etiology is not precisely known, Merkel cell polyomavirus DNA has been found recently in a large percentage of MCC tumors. Other suggested risk factors include sun exposure, immunosuppression, and a history of prior malignancy. Work up of patients with MCC most notably includes nodal staging via clinical examination or sentinel lymph node biopsy. The prognosis for most patients with MCC is poor, and the rarity of MCC precludes the prospective, randomized clinical trials necessary to elucidate optimum treatment protocols. Most published data support the use of a multimodality approach centered around surgical excision with negative margins, sentinel lymph node biopsy to establish the presence or absence of nodal metastases, adjuvant radiothearpy to decrease the risk of recurrence, and systemic chemotherapy in the case of widespread disease.
M erkel cell carcinoma (MCC) was initially described by Toker in 1972 1 as a trabecular cancer of the dermis with high lymphatic metastatic risk and found mainly in White elderly patients. The past 2 decades have given rise to a growing interest in characterization of the disease and the best approach to its management. Numerous submitted case reports demonstrate that MCC is a rare, clinically aggressive neuroendocrine tumor of the skin with a high propensity for local, regional, and distant spread. MCC is lethal in 33% of cases and therefore carries a worse prognosis than malignant melanoma. 2 The number of cases of MCC reported annually in the United States is quickly rising, likely secondary to advances in diagnostic techniques, a growing elderly population, and a larger number of immunosuppressed patients. Treatment options vary from surgery alone to multimodality therapy including surgery, radiation therapy (RT), and chemotherapy (CT). This article will highlight recent developments in the biology and management of patients with MCC.
DISCUSSION Biology
The Merkel cell (MC) was first described by Friedrich Sigmund Merkel in 1875 as a nondendritic, nonkeratinocyte epidermal ''tastzellen'' or ''touch cell'' that functions as a tactile skin receptor. 3, 4 Although the true function remains enigmatic, it is presumed that the normal MC may play a role in signal transduction and function as slowly adapting mechanoreceptors to sense touch and hair movement. 5, 6 Continued advances in identifying unique immunocytochemical staining patterns in MC has allowed the diagnostician to more readily identify cases of MCC, increasing both recognition of true disease prevalence and rapid delivery of appropriate treatment. [7] [8] [9] [10] In addition, the presence of cytoplasmic neurosecretory granules, cytoplasmic processes, and intermediate filaments surrounding the nucleus, demonstrated on electron microscopy, can be used to confirm the identity of MC as the progenitor line in MCC. [11] [12] [13] Etiology Although the specific etiology of MCC is not clearly known, probable risk factors have been indicated by published case reports, case series, and population-based studies. A history of sun exposure or concurrence of other sun-associated skin conditions, particularly squamous cell carcinoma, is common in patients with MCC. [14] [15] [16] Studies have also shown an increased incidence of MCC in patients on immunosuppressive agents for solid organ transplant, [17] [18] [19] in patients with human immunodeficiency virus infection and low CD4 counts, 20, 21 in patients undergoing radiation or CT, 22, 23 and in patients chronically exposed to arsenic. 24 More recently, autoimmune disease has been suggested as a risk factor for developing MCC. 25 The most notable recent discovery concerning the pathogenesis of MCC is the characterization of a new polyomavirus named Merkel cell polyomavirus (MCV) by Moore and Chang. 26 Polyomaviruses have a double-stranded, circular, supercoiled DNA genome and have been shown to have oncogenic potential. 27 Feng et al 26 discovered and sequenced the genome of MCV and identified MCV DNA in 8 of 10 MCC tumors. Since the original report, a multitude of other groups have found MCV DNA in MCC tissue samples. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] Although MCV DNA can be helpful in distinguishing MCC from other cutaneous neoplasms and in identifying the primary tumor in metastatic disease, Tolstov et al 42 report 50% and 80% prevalence of MCV antibodies among people under 15 years of age and older than 50 years of age, respectively. Some authors suggest vaccination with MCV virus-like particles could potentially prevent initial MCV infection, although only small pilot animal studies have been performed thus far. 43 
Epidemiology
Conflicting nomenclature, ill-defined diagnostic methods and criteria, and a paucity of reported cases are issues that have been addressed as more aggressive and widespread study of the disease has been undertaken. As a more standardized approach to staging ( Table 1) 44 and International Classification of Diseases 9 coding (Table 2) have been implemented, a more reliable population-based registry of MCC over large geographic areas has become available. Using the Surveillance Epidemiology and End Results cancer registry database of the National Cancer Institute, the estimated overall incidence of first primary MCC in the USA for the decade 1992 to 2001 is 0.32 per 100,000 personyears. As the majority of MCC cases have been diagnosed since the establishment of a specific immunologic profile for MCC in 1992, calculation of the increasing incidence of first primary MCC in the general population should use 1992 as the year of reference. 45 Demographically, MCC is found most frequently in the elderly, with only sporadic cases reported before the age of 50 years. The incidence of MCC in Whites is more than 8 times that in Blacks and almost double the incidence of other ethnic groups. The incidence of first primary MCC is higher in males than females in all ethnic groups, with a ratio of 2:1 in White and in Black, and a ratio of 1.5:1 in all other ethnic groups. 45, 46 Clinical Presentation MCC has been described in the literature as a classically painless subcutaneous mass with a cystic or nodular appearance, but sometimes presenting with a plaque-like appearance that may be surrounded by small satellite lesions. The tumor size ranges from 2 to 200 mm, but is most often <20 mm. 3, 47 Lesions can vastly range in color, most often presenting as red/pink, blue/ violaceous, or skin colored. 47 They can exhibit overlying telangiectasia or a shiny surface, making lesions easily confused with basal cell carcinoma. 48 Figures 1A to C illustrate various MCC at presentation. Tumors may exhibit rapid growth in the preceding weeks or months 3 with a mean length of time of 6.2 months (2 wk to 2 y) between the patient noticing the lesion and presenting for histologic diagnosis. 45 Although the majority of cases present in sun-exposed areas, it is important to note that the neoplasm can also present in areas of minimal sun exposure. Various sources cite the incidence of disease of the head and neck to account for approximately 50% of cases, followed in decreasing order by the extremities, trunk, and buttock. 3 Studies show 71% to 79% of patients present with clinically negative nodal involvement (stages I and II disease), 19% to 24% present with regional nodal metastasis (stage III disease), and 5% have evidence of distant metastatic disease (stage IV disease). 49, 50 Secondary sites of involvement include skin (28%), lymph nodes (27%), liver (13%), lung (10%), bone (10%), and brain (6%). 3, 48 
Diagnosis and Differential Diagnosis
The physical characteristics of MCC can resemble those of an epidermoid cyst, lipoma, dermatofibroma, amelanotic melanoma, basal cell carcinoma, squamous cell carcinoma, lymphoma, sarcoma, or metastatic carcinoma. 51 Tis  N0  M0  IA  T1  pN0  M0  IB  T1  cN0  M0  IIA  T2/T3  pN0  M0  IIB  T2/T3  cN0  M0  IIC  T4  N0  M0  IIIA  Any T  N1a  M0  IIIB  Any T  N1b/N2  M0  IV Any T Any N M1 Code Name 209. 31 Merkel cell carcinoma of the face 209. 32 Merkel cell carcinoma of the scalp and neck 209. 33 Merkel cell carcinoma of the upper limb 209. 34 Merkel cell carcinoma of the lower limb 209. 35 Merkel cell carcinoma of the trunk 209. 36 Merkel cell carcinoma of other sites 209. 75 Secondary Merkel cell carcinoma V10. 91 Personal history of malignant neuroendocrine tumor suggest the use of the mnemonic AEIOU to list significant characteristics: Asymptomatic, Expanding rapidly (doubling in <3 mo), Immune suppressed, Older than 50 years of age, and Ultraviolet exposed skin site, with a subcategory of fair skin). In the 62 patients for which all 5 criteria were available, at least 3 criteria were fulfilled by 89% of patients, at least 4 by 32%, and all 5 were seen in 6% of patients. However, the key to establishing and accurate of and timely diagnosis of MCC is a low clinical index of suspicion and prompt biopsy. 51 Under light microscopy, MCC presents as an intradermal mass, separated from the epidermis by a narrow ''Grenz zone'' often with necrosis (apoptotic bodies) and patchy lymphocytic infiltrates. 52 Figures 2A and B demonstrate some pathologic features of MCC, characterized by neurosecretory granules, cytoplasmic processes, and intermediate filaments surrounding the nucleus. In addition to the specific clinical and histologic features, MCC is confirmed by immunohistochemistry for proteins such as CK-20, which is detected in a characteristic paranuclear dot-like pattern in 89%-100% of MC tumors but is rarely positive in SCC (Figs. 2C, D). 8 
Work Up
Initial staging of MCC should include evaluation of primary site for satellite lesions and dermal seeding. Draining nodes should be palpated. Full blood count, serum electrolytes, and alkaline phosphatase are useful in providing a baseline. 48 Initial imaging workup based on severity of disease based on clinical presentation. Patients with localized disease without physical or symptomatic evidence of regional or distant metastases should be evaluated for spread to regional nodal basins with sentinel lymph node biopsy (SLNB) or ultrasound. 53 Patients with lesions suspicious for regional lymph node involvement can undergo fine needle aspiration cytology, often with ultrasound guidance for more accurate sampling. When lymph nodes are positive, full body imaging is generally indicated to detect distant metastases. 53 This can be accomplished with a variety of imaging modalities (Figs. 3A-D), with mounting evidence demonstrating the utility of fluorodeoxyglucose positron emission tomography (FDG-PET) imaging in the staging and management of MCC. [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] In a recent study of 18 patients, staging was adjusted in 33% of patients, and the treatment approach was altered in 43% of patients after results of FDG-PET were obtained. 55 Figure 3C shows a patient with MCC of the mandible who was found to have metastatic disease to the mediastinum and liver on posttreatment follow-up FDG-PET scan, and Figures 3D illustrates the detection of an involved iliac node from a small foot primary MCC by positron emission tomography computed tomography scan.
High resolution computed tomography and magnetic resonance can be used for clinical problem solving in special circumstances. 53 Computed tomography is useful for imaging of the thorax and abdomen to exclude metastatic lesions ( Fig. 3A ) and primary SCLC, and can also be used to image deeper lymph nodes and nodular metastases in subcutaneous fat. 48, 54 Magnetic resonance has been recommended for local imaging and regional lymph node staging for patients with MCC (Fig. 3B) , and in particular for evaluation of local tumor spread in regions not easily accessible by sonography and the deeper fascia of the head and neck region such as the sinonasal region and orbit. 
Prognostic Factors
Based on an analysis of prognostic factors in 5823 patient cases for the development of a consensus system by the American Joint Committee on Cancer, extent of disease at presentation is highly predictive of survival. This is in concordance with prior studies and staging systems. 50, 64, 65 In this study, it was shown that survival at 5 years (relative to age and sex-matched control/population data) was 64% for local (stage I or II), 39% for regional nodal (stage III), and 18% for distant metastatic (stage IV) disease. 51, 66, 67 In particular, extent of nodal involvement has been shown to have an impact on survival, with a 42% survival at 5 years in patients with only microscopic nodal involvement and 26% survival for those with clinically apparent nodal disease. 51, 66, 67 The impact of this distinction is reflected in the new staging system ( Table 1) .
The prognostic value of tumor thickness is an area of continued study and controversy. Although some researchers have suggested that tumor thickness is positively associated with likelihood of nodal metastasis and poor survival, others have denied this association. [68] [69] [70] Other patient and tumor characteristics often considered to portend poor outcome include male sex, age greater than 60 years, presence of comorbid conditions, immunocompromised state, positive resection margin, high mitotic rate, small cell size, absence of an inflammatory infiltrate, primary site of disease (head/ neck, trunk, perineum, lower extremities), and no adjuvant radiotherapy. 7, 10, 45, 64 Prognostic factor analyses of the impact on survival in larger scale studies are required to determine the true prognostic value of these characteristics.
Treatment Options
The treatment of choice for MCC depends on many factors including the stage of the tumor, particularly with respect to nodal involvement, the location of the tumor, and the medical comorbidities of the patient. Though far from a consensus, most current recommendations include the addition of adjuvant RT to reduce local or nodal relapse and to improve disease specific and overall survival. A summary of results and recommendations from recent retrospective reviews and metaanalyses is provided in Table 3 .
Surgical Intervention
The standard of surgical care for MCC has traditionally been wide local excision. Some experts have suggested surgery alone is adequate for early stage disease, 80, 84, 85 but a recent study of 95 patients from a database at the National Cancer Institute in Milan further evaluated the use of surgery alone in early stage MCC. 75 The authors report an 80% 5-year diseasespecific survival rate when lymph nodes were pathologically negative, which dropped to 58% when regional nodal metastases were present. Although it was initially thought that margins Z3 cm were necessary for the best reduction of local recurrence, 86,87 margins 2 to 3 cm wide and 2 cm deep are now generally accepted. 52, [88] [89] [90] Allen et al 91 reviewed records of 102 patients with MCC treated at Memorial Sloan-Kettering Cancer center over a 27-year period and found no association between width of margins and either recurrence rate or survival. Two additional studies showed no difference in locoregional control or overall survival regardless of margin status. 92, 93 As with more common skin cancers, Mohs microsurgery is an attractive treatment option for tumors on the head and neck, where the recommended margin width and depth are either cosmetically undesirable or technically impossible. Boyer et al 85 studied recurrence rates and survival in patients with stage I MCC treated with Mohs surgery with or without adjuvant RT and concluded that the addition of adjuvant RT after Mohs surgery was not necessary as it did not provide additional benefit in terms of recurrence or survival. O'Connor et al 94 
evaluated patients treated with wide local excision or
Mohs surgery and found that, although standard surgical excision resulted in local persistence and regional metastasis in 31.7% and 48.8% of patients, respectively, Mohs surgery resulted in only 6.8% and 33.3% local persistence and regional metastasis, respectively. O'Connor et al suggested that there may be some benefit in adding adjuvant RT after Mohs surgery to further reduce the risk of nodal metastasis.
Another point of disagreement among surgeons is whether or not SLNB or lymph node dissection (LND) is necessary for patients undergoing surgical excision of MCC. Even in patients with no clinical evidence of lymph node involvement, 25% to 100% of primary draining lymph nodes may contain microscopic metastases 91, [95] [96] [97] that can lead to nodal relapse in up to 76% of patients. 52, [98] [99] [100] As MCC is thought to spread in an orderly fashion similar to melanoma, SLNB can detect subclinical nodal metastatic disease before progression to stage IV disease [101] [102] [103] Allen et al 80 showed data suggesting incidence of positive lymph nodes was independent of tumor size, so routine SLNB should be offered to all patients undergoing surgical excision for MCC. Fang et al 71 also describe the morbidity owing to LND and offer data to suggest lymph node irradiation can provide comparable control rates to LND whether lymph node disease is detected clinically or by SLNB.
RT
RT has been advocated by a few authors as definitive treatment, particularly for patients who are poor surgical candidates. 76, 104 Although RT is typically added when patients present at a higher stage or with nodal metastases, Mortier et al 104 reported data on 26 patients with stage I MCC. There was no difference in disease specific or overall survival between patients with stage I MCC treated with RT alone or surgery + RT. The 9 patients treated with definitive RT received a median dose of 60 Gy, and the majority received prophylactic nodal irradiation. More recently, Veness et al 76 presented an analysis of 46 patients treated with definitive RT. Included patients were inoperable either owing to advanced disease or because of medical comorbidities. In fact, 77% of the patients examined had nodal metastases at the time of treatment. A slightly lower mean radiation dose was used for the nodal basins (51 to 55 Gy), but the authors reported a 75% in-field control rate. Even though the numbers are small, these 2 studies show that RT may be a viable alternative to surgery for patients unable to withstand an operation, but adjuvant or concurrent RT to the nodal basins is recommended even in patients presenting with stage I disease.
There have been few studies examining the optimum RT dose for the treatment of MCC. The similarities between MCC and SCLC have led to the common use of doses of 45 to 60 Gy, depending on the presence or absence of gross disease. Morrison et al 105 recommend 56 to 60 Gy for gross unresected disease and 46 to 50 Gy for adjuvant treatment of the primary tumor site and draining lymphatics after resection. A more recent study confirmed the role of RT in reducing local and nodal relapses and demonstrated a dose-response relationship of up to 50 Gy for subclinical disease and greater than 55 Gy for gross disease. 72 The majority of retrospective studies conducted over the past 15 years have consistently demonstrated better local control after surgery when adjuvant RT is <0.001 Recommend adjuvant RT for improvement of regional control rates added. [72] [73] [74] [77] [78] [79] 81, 92, 106, 107 In one of the largest single institution studies, Gillenwater et al 92 analyzed 66 cases of MCC of the head and neck treated at M.D. Anderson Cancer Center. Although width of surgical margins did not significantly affect survival, the authors did report significantly lower local and regional recurrence rates in the 26 patients receiving postoperative RT, even in the 77% of patients with clinically negative lymph nodes. In contrast, Allen et al 80 published the largest single institution study to date and found no difference in local or regional recurrence upon the addition of adjuvant RT. 
CT
As is the case with RT doses and schedules, the majority of the chemotherapeutic regimens used to treat MCC are similar to those found to be effective in the treatment of SCLC. Carboplatin, cisplatin, etoposide, cyclophosphamide, 5-fluorouracil, vincristine, and doxorubicin are some of the more common agents used. Traditionally, primary CT has been reserved for those patients with unresectable disease, whether owing to poor surgical candidacy because of metastatic disease or owing to medical comorbidities. Adjuvant CT has been suggested to be of benefit when added to surgery and adjuvant RT for the treatment of stage II disease. 48 In a study of 40 patients with stages I and II MCC, Poulsen et al 109 showed no beneficial effect of CT, but reported wide confidence intervals and an underpowered study. In addition to the small number of MCC patients treated with CT, the advanced stage at which CT is added makes drawing definitive conclusions problematic. In a study of 35 patients, Kokoska et al 110 reported no benefit when CT was added to adjuvant therapy regimens. Likewise, Allen et al 80 reported no benefit in survival upon the addition of adjuvant CT. Conversely, several authors have reported CT to be beneficial in terms of recurrence and survival especially for patients with high-risk MCC. 82, 91, 105, 107 Two retrospective analyses sought to further characterize the use of CT for MCC with larger groups of patients. 111, 112 Voog et al 111 reported an impressive 61% response rate (57% for metastatic disease and 69% for advanced disease). However, the authors found that while MCC is chemosensitive, it is rarely curable, and the 7.7% risk of toxic death owing to neutropenia further complicates the treatment decision. Tai et al 112 analyzed a larger group of patients treated with CT and found an even more impressive response rate of 75.7%.
CONCLUSIONS
Recent developments have improved accuracy in diagnosing MCC, and the discovery of MCV DNA in MCC tumors has shed considerable light on the pathogenesis. Although the free survival; RR, regional recurrence; RRFS, regional recurrence free survival; RT, radiation therapy; S, surgery; SEER, Surveillance Epidemiology and End Results; SLNB, sentinel lymph node biopsy.
incidence has been shown to be increasing, there are still far too few cases of MCC presenting to any one institution for definitive conclusions to be drawn. Collaboration will be the key to future breakthroughs in terms of diagnosis, prognosis, and treatment of this rare neoplasm. The consensus staging system and revised International Classification of Diseases 9 codes are 2 steps taken recently in standardizing the way MCC cases are reported. A definitive staging system may be a first important step in making possible a world-wide, multiinstitutional prospective, randomized case-control study to definitively determine whether a multimodality regimen is superior to surgical resection alone in the treatment MCC. Such large scale trials will also be necessary to answer existing questions concerning the use of CT. Until such data becomes available, there is ample data to advocate for the use of adjuvant RT after surgical resection owing to the high incidence of local, nodal, and distant metastatic relapse. Although MCC is chemosensitive, there is less data on the efficacy of CT, and its role in adjuvant therapy continues to be debated.
